NantHealth and NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tumor Infiltrating Killer Cells From Whole Slide Images

Stock Information for NantHealth Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NantHealth Inc.

NantHealth's Eviti Connect Achieves HITRUST Risk-based, 2-year Certification to Further Mitigate Risk in Third-Party Privacy, Security and Compliance
NantHealth Announces $22.5 Million New Financing with Highbridge and Nant Capital
OpenNMS releases OpenNMS Meridian 2023 with New Cloud-enabled Capabilities
NantHealth Announces 1-for-15 Reverse Stock Split
NantHealth Reports 2022 Third Quarter Financial Results
NantHealth to Report 2022 Third-Quarter Financial Results and Host Conference Call on Thursday, November 3
NantHealth's Eviti Platform Once More Earns Full URAC Accreditation Through 2025
NantHealth Reports 2022 Second Quarter Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.